Small-Molecule APIs

Unlocking the Best Solution for API Sourcing

April 02, 2018

CMOs/CDMOs that are easy to work with, have demonstrated performance track records, and plan for the future are preferred.

Can Early Development Strategies Avoid Later-Stage Disasters?

March 02, 2018

Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.

Small Volumes, Big Challenges

March 02, 2018

Highly complex APIs developed to treat rare and orphan diseases present big technical questions for contract developers.

Cambrex Expands API Development at Iowa Facility

February 01, 2018

Cambrex invests in development and laboratory facilities and adds staff.

Avista Pharma Acquires Solid Form Solutions

February 01, 2018

Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.

Cambrex and AstraZeneca Mark Long-Term Supply Agreement at Sweden Site

January 16, 2018

A ceremony was held at Cambrex’s Karlskoga facility to mark the commencement of a long-term manufacturing agreement with AstraZeneca for a key intermediate.

FDA Ramped Up Approval Rate in 2017

January 02, 2018

FDA looks to achieve near-record level of new drug approvals following slowdown in 2016.

Nanoparticle Reactor Technology Controls Particle Size and Distribution

December 18, 2017

MJR PharmJet's MicroJet Reactor technology is a continuous process for producing nanoparticles with tightly controlled particle size and particle size distribution.

Hazardous Chemistry: Choosing Batch or Flow

December 02, 2017

For many processes involving hazardous chemistry, running in flow mode has safety and economic advantages.

Avista Doubles API Manufacturing Capacity at Colorado Facility

November 20, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

Avista Pharma Solutions facility and equipment upgrades at its Longmont, Colorado facility support processing of potent compounds.